New tests for coagulation and lysis monitoring system in Cardiovascular Diagnostics' pipeline
This article was originally published in Clinica
Executive Summary
Cardiovascular Diagnostics (US) plans to introduce new tests for its Thrombolytic Assessment System (TAS) in certain European markets this year and submit the tests for US 510(k) clearance. The North Carolina-based company claims TAS is the only point-of-care stat system capable of monitoring both the coagulation and lysis of blood clots.